Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nicotine‐Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence
Raymond F. Anton, Patricia K. Latham, Konstantin Voronin, et al.
Alcoholism Clinical and Experimental Research (2018) Vol. 42, Iss. 4, pp. 751-760
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Advances in the science and treatment of alcohol use disorder
Katie Witkiewitz, Raye Z. Litten, Lorenzo Leggio
Science Advances (2019) Vol. 5, Iss. 9
Open Access | Times Cited: 442
Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms
Raymond F. Anton, Patricia K. Latham, Konstantin Voronin, et al.
JAMA Internal Medicine (2020) Vol. 180, Iss. 5, pp. 728-728
Open Access | Times Cited: 151
Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta‐analysis
Lara A. Ray, ReJoyce Green, Daniel Roche, et al.
Addiction Biology (2019) Vol. 24, Iss. 6, pp. 1138-1152
Open Access | Times Cited: 48
Systematic review and meta‐analysis of the moderating effect of rs1799971 in OPRM1, the mu‐opioid receptor gene, on response to naltrexone treatment of alcohol use disorder
Emily E. Hartwell, Richard Feinn, Paige E. Morris, et al.
Addiction (2020) Vol. 115, Iss. 8, pp. 1426-1437
Open Access | Times Cited: 33
Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial
Lara A. Ray, ReJoyce Green, Craig K. Enders, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 9, pp. 818-828
Open Access | Times Cited: 29
Endogenous Opiates and Behavior: 2018
Richard J. Bodnar
Peptides (2020) Vol. 132, pp. 170348-170348
Closed Access | Times Cited: 21
Reward drinking and naltrexone treatment response among young adult heavy drinkers
Corey R. Roos, Krysten W. Bold, Katie Witkiewitz, et al.
Addiction (2021) Vol. 116, Iss. 9, pp. 2360-2371
Open Access | Times Cited: 20
Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving
Bart de Laat, Nabeel Nabulsi, Yiyun Huang, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 9, pp. 5053-5060
Closed Access | Times Cited: 19
Effects of ethanol, naltrexone, nicotine and varenicline in an ethanol and nicotine co-use model in Sprague-Dawley rats
Cassie M. Chandler, Sarah E. Maggio, Hui Peng, et al.
Drug and Alcohol Dependence (2020) Vol. 212, pp. 107988-107988
Open Access | Times Cited: 13
An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence
Yufei Lin, Henry R. Kranzler, Lindsay A. Farrer, et al.
The Pharmacogenomics Journal (2020) Vol. 20, Iss. 5, pp. 672-680
Open Access | Times Cited: 11
Smoking As an Outcome Moderator In the Treatment of Alcohol Use Disorders
Jan van Amsterdam, Wim van den Brink
Alcohol and Alcoholism (2022)
Open Access | Times Cited: 7
Nicotine increases alcohol self‐administration in male rats via a μ‐opioid mechanism within the mesolimbic pathway
Esi Domi, Li Xu, Marvin Pätz, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 19, pp. 4516-4531
Open Access | Times Cited: 8
Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial
Raymond F. Anton, Konstantin Voronin, Sarah W. Book, et al.
Alcoholism Clinical and Experimental Research (2020) Vol. 44, Iss. 10, pp. 2084-2096
Open Access | Times Cited: 8
Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers
Erica N. Grodin, Elizabeth M. Burnette, ReJoyce Green, et al.
Drug and Alcohol Dependence (2021) Vol. 225, pp. 108825-108825
Open Access | Times Cited: 7
Genetic deletion or pharmacological blockade of nociceptin/orphanin FQ receptors in the ventral tegmental area attenuates nicotine‐motivated behaviour
Ana Domi, Veronica Lunerti, Michele Petrella, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 11, pp. 2647-2658
Open Access | Times Cited: 6
Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels
Steven J. Nieto, Craig K. Enders, Katie Witkiewitz, et al.
Alcoholism Clinical and Experimental Research (2022) Vol. 46, Iss. 12, pp. 2258-2266
Closed Access | Times Cited: 4
Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
ReJoyce Green, Spencer Bujarski, Aaron C. Lim, et al.
Experimental and Clinical Psychopharmacology (2019) Vol. 27, Iss. 3, pp. 257-264
Open Access | Times Cited: 5
Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications
Alexandra Venegas, Lindsay R. Meredith, Ziva D. Cooper, et al.
Alcohol and Alcoholism (2020) Vol. 55, Iss. 4, pp. 416-423
Open Access | Times Cited: 3
Education Intervention to Increase Naltrexone Use Among Adult Inpatients With Alcohol Use Disorder
Jason Ipsarides
Journal of Psychosocial Nursing and Mental Health Services (2023) Vol. 61, Iss. 9, pp. 10-14
Closed Access | Times Cited: 1
Evidence of subgroup differences in meta‐analyses evaluating medications for alcohol use disorder: An umbrella review
Joshua D. Wallach, Laura Glick, Ralitza Gueorguieva, et al.
Alcohol Clinical and Experimental Research (2023) Vol. 48, Iss. 1, pp. 5-15
Closed Access | Times Cited: 1
Midazolam, methamphetamine, morphine and nicotine intake in high‐drinking‐in‐the‐dark mice
Antonia M. Savarese, Pamela Metten, Tamara J. Phillips, et al.
Addiction Biology (2022) Vol. 27, Iss. 5
Open Access | Times Cited: 2
Rates of Prescription Orders for United States Active Duty Service Members Diagnosed with Alcohol use Disorder
Zachary Peters, Melissa W. Kincaid, Jennifer G. Greenberg, et al.
Substance Abuse (2020) Vol. 42, Iss. 4, pp. 638-645
Open Access | Times Cited: 1
Topiramate, Naltrexone, and Acamprosate in the Treatment of Alcohol Use Disorders
Riccardo Guglielmo, Liana Kobylinska, Rocco de Filippis
Springer eBooks (2021), pp. 1-16
Closed Access | Times Cited: 1
Changed Primary Outcome Between Trial Registration and Publication—Reply
Raymond F. Anton, Michaela Hoffman
JAMA Internal Medicine (2020) Vol. 180, Iss. 11, pp. 1551-1551
Closed Access
Topiramate, Naltrexone, and Acamprosate in the Treatment of Alcohol Use Disorders
Riccardo Guglielmo, Liana Kobylinska, Rocco de Filippis
Springer eBooks (2022), pp. 2535-2550
Closed Access
Page 1 - Next Page

Scroll to top